Skip to main content

Table 2 Treatment patterns during the first MITT episode (N = 37,400)

From: Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea

Characteristics of first MITT

Observation period, days, mean (SD) [median (IQR)]

960.5 (314.5) [980 (687, 1240)]

MITT at index date

 ICS + LABA + LAMA, n (%)

99 (0.3)

  Duration, days, mean (SD)

223.0 (310.8)

  Discontinuation, n (%)

96 (97.0)

 ICS + LABA/LAMA, n (%)

1935 (5.2)

  Duration, days, mean (SD)

240.6 (250.0)

  Discontinuation, n (%)

1697 (87.7)

 ICS/LABA + LAMA, n (%)

35,364 (94.6)

  Duration, days, mean (SD)

220.8 (267.8)

  Discontinuation, n (%)

32,469 (91.8)

  1. ICS: inhaled corticosteroids; IQR: interquartile range; LABA: long-acting beta-agonist; LAMA: long-acting muscarinic antagonist; MITT: multiple inhaler triple therapy; SD: standard deviation
  2. MITT was defined as concomitant use of two different inhalers in the form of ICS/LABA + LAMA or ICS + LABA/LAMA, or of three different inhalers in the form of ICS + LAMA + LABA. The observation period comprised the time from index date until end of data availability